Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1992 2
1994 2
1995 1
1996 1
1997 1
1998 6
1999 4
2000 5
2001 6
2002 5
2003 5
2004 7
2005 4
2006 2
2007 4
2008 5
2009 8
2010 10
2011 7
2012 8
2013 6
2014 8
2015 12
2016 8
2017 9
2018 9
2019 8
2020 16
2021 11
2022 16
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Behçet Uveitis.
Cunningham ET Jr, Tugal-Tutkun I, Khairallah M, Okada AA, Bodaghi B, Zierhut M. Cunningham ET Jr, et al. Among authors: okada aa. Ocul Immunol Inflamm. 2017 Feb;25(1):2-6. doi: 10.1080/09273948.2017.1279840. Ocul Immunol Inflamm. 2017. PMID: 28195819 No abstract available.
COVID Vaccine-Associated Uveitis.
Habot-Wilner Z, Neri P, Okada AA, Agrawal R, Xin Le N, Cohen S, Fischer N, Kilmartin F, Coman A, Kilmartin D. Habot-Wilner Z, et al. Among authors: okada aa. Ocul Immunol Inflamm. 2023 Aug;31(6):1198-1205. doi: 10.1080/09273948.2023.2200858. Epub 2023 May 5. Ocul Immunol Inflamm. 2023. PMID: 37145198 Review.
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, Ohsawa S, Okada AA; TENAYA and LUCERNE Investigators. Mori R, et al. Among authors: okada aa. Jpn J Ophthalmol. 2023 May;67(3):301-310. doi: 10.1007/s10384-023-00985-w. Epub 2023 Apr 11. Jpn J Ophthalmol. 2023. PMID: 37039948 Free PMC article. Clinical Trial.
Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan.
Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Hashiya N, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T. Mukai R, et al. Among authors: okada aa. Sci Rep. 2023 May 30;13(1):8747. doi: 10.1038/s41598-023-35759-4. Sci Rep. 2023. PMID: 37253802 Free PMC article.
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; ALTAIR Investigators. Ohji M, et al. Among authors: okada aa. Adv Ther. 2020 Mar;37(3):1173-1187. doi: 10.1007/s12325-020-01236-x. Epub 2020 Feb 3. Adv Ther. 2020. PMID: 32016788 Free PMC article. Clinical Trial.
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, Yamamoto A, Mukai R, Honjyo J, Maruko I, Kawai M, Miyara Y, Terao N, Wakatsuki Y, Onoe H, Mori R, Koizumi H, Sekiryu T, Iida T, Okada AA; for Japan AMD Research Consortium (JARC). Kataoka K, et al. Among authors: okada aa. Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):43-51. doi: 10.1007/s00417-023-06222-x. Epub 2023 Sep 5. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 37668741
Topical antibiotics and intravitreal injections.
Hunyor AP, Merani R, Darbar A, Korobelnik JF, Lanzetta P, Okada AA. Hunyor AP, et al. Among authors: okada aa. Acta Ophthalmol. 2018 Aug;96(5):435-441. doi: 10.1111/aos.13417. Epub 2017 Apr 25. Acta Ophthalmol. 2018. PMID: 28440583 Free article. Review.
Epidemiology of Macular Edema in Uveitis.
Accorinti M, Okada AA, Smith JR, Gilardi M. Accorinti M, et al. Among authors: okada aa. Ocul Immunol Inflamm. 2019;27(2):169-180. doi: 10.1080/09273948.2019.1576910. Epub 2019 Mar 1. Ocul Immunol Inflamm. 2019. PMID: 30821631 Review.
Reply.
Koizumi H, Yamamoto A, Maruko I, Okada AA, Iida T, Kano M, Saito M, Sekiryu T, Kawasaki R. Koizumi H, et al. Among authors: okada aa. Am J Ophthalmol. 2016 Aug;168:287-288. doi: 10.1016/j.ajo.2016.05.004. Epub 2016 Jun 2. Am J Ophthalmol. 2016. PMID: 27265886 No abstract available.
Reply.
Okada AA, Yamamoto A, Koizumi H, Kano M, Saito M, Maruko I, Sekiryu T, Iida T. Okada AA, et al. Ophthalmology. 2016 Feb;123(2):e13-e14. doi: 10.1016/j.ophtha.2015.08.032. Ophthalmology. 2016. PMID: 26802715 No abstract available.
173 results